Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Crexendo (NASDAQ:CXDO) Stock: 44% Revenue Growth and USD 140 Million Backlog in Focus Near 52-Week Low

Crexendo has a marketCapitalizationof about USD 170.38 million and a price toEarningsratio of 42.44. It had 33,375,586 shares outstanding as of October 31, 2026.

Nitish Kishor | 08 November 2026

CrossAmerica Partners (NYSE:CAPL) Holds Near a 52-Week Low as Fuel Volume Pressures Third Quarter Earnings

CrossAmerica has a marketCapitalizationof about USD 753.16 million and a price toEarningsratio of 14.40. It had 38,173,255 common units outstanding as of October 30, 2026.

Nitish Kishor | 08 November 2026

Why Is Dutch Bros (NYSE:BROS) Near a 52-Week Low Despite 30% Third Quarter Revenue Growth?

Dutch Bros has a marketCapitalizationof about USD 5.93 billion and a price toEarningsratio of 47.89. It operates and franchises drive-thru shops, with 1,273 shops as of September 30, 2026.

Nitish Kishor | 08 November 2026

Peabody Energy (NYSE:BTU) Trades Near a 52-Week Low as Third Quarter Revenue Climbs 8%

Peabody has a marketCapitalizationof about USD 1.99 billion at the current price. It is a leading producer of metallurgical and thermal coal that sold 122.0 million tons in 2025, and it had 121.9 million shares outstanding at November 2, 2026.

Nitish Kishor | 08 November 2026

Saul Centers (NYSE:BFS) Stock: Third Quarter Revenue Rises 9% as Shares Trade Near a 52-Week Low

Saul Centers has a marketCapitalizationof about USD 705.43 million and a price toEarningsratio of 29.38. As of September 30, 2026, its portfolio consisted of 50 shopping centers, nine mixed-use properties and three non-operating development properties.

Nitish Kishor | 08 November 2026

Why Did Cogent Communications (NASDAQ:CCOI) Stock Fall 17% to a 52-Week Low?

Cogent has a marketCapitalizationof about USD 198.72 million at the current price. It had 51,203,883 shares outstanding as of October 31, 2026.

Nitish Kishor | 08 November 2026

Johnson & Johnson Phase 1 Data: Pasritamig Plus JNJ-9401

Johnson & Johnson (NYSE:JNJ) disclosed Phase 1 clinical results for the investigational combination of pasritamig and JNJ-9401 in metastatic castration-resistant prostate cancer, presented at the Society for Immunotherapy of Cancer 2026 Annual Meeting on November 8, 2026.

Shwetambri Chauhan | 08 November 2026

AeroVironment (NASDAQ:AVAV) Jumps 10% Near a 52-Week Low as Funded Backlog Hits Record USD 1.5 Billion

Revenue was USD 480,490 thousand against USD 454,676 thousand. GrossMarginwas USD 124,599 thousand against USD 95,118 thousand, and cost of sales fell from 79% to 74% of revenue, with intangible amortization and other purchase accounting expenses of USD 18.6 million against USD 37.4 million. …

Nitish Kishor | 07 November 2026

Why Did AGNT, Inc. (NASDAQ:AGNT) Shares Slide 15% Toward a 52-Week Low?

AGNT has a marketCapitalizationof about USD 555.67 million at the current price. It operates a diversified portfolio of service based businesses on an enabling technology platform, with most revenue coming from commissions earned by its residential real estate brokerages.

Nitish Kishor | 07 November 2026

Akebia Therapeutics (NASDAQ:AKBA) Stock Down 5%: Revenue Falls to USD 36.9 Million as Shares Near 52-Week Low

Akebia has a marketCapitalizationof about USD 112.17 million at the current price. It is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease, Auryxia and Vafseo.

Nitish Kishor | 07 November 2026
Support

Hi! How can we help you today?

Loading…